Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Freya Biosciences
AddedFeb 17, 2024
UpdatedJul 22, 2026
Freya Biosciences

Freya Biosciences

Freya Biosciences: Pioneering microbial immunotherapies for women's health, based in Boston and Copenhagen.

HQ
Boston, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Founded in Boston and Copenhagen, Freya Biosciences is a clinical-stage company dedicated to advancing women's health through pioneering microbial immunotherapies. Their core mission is to address significant unmet needs in women's health, particularly focusing on fertility issues. Freya Biosciences offers innovative treatments aimed at improving outcomes for couples facing infertility, leveraging cutting-edge microbial science to develop effective therapies.

Freya Biosciences has attracted notable experts and investors in the biotech and healthcare sectors, contributing to its rapid growth and recognition. The company has achieved significant milestones, including successful clinical trials and strategic partnerships with leading research institutions. By focusing on microbial immunotherapies, Freya Biosciences is making a substantial impact on women's health, offering new hope for those struggling with infertility and setting new standards in medical treatment.

Freya Biosciences - Quick Facts

When was Freya Biosciences founded?

Freya Biosciences was founded in 2020.

Where is Freya Biosciences' headquarters located?

Freya Biosciences' headquarters is located in Boston, MA, US.

When was Freya Biosciences' last funding round?

Freya Biosciences' most recent funding round was for $38M (USD) in December 2023.

How much has Freya Biosciences raised to-date?

As of Dec 12, 2023, Freya Biosciences has raised a total of $38M (USD).

How many employees does Freya Biosciences have?

Freya Biosciences has 6 employees as of Feb 4, 2024.

Freya Biosciences - Classification

Industry
  • Therapeutics
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Consumers
Main Product
  • Immunotherapies
Tags
  • Biotech
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified